Plenary Session: 3.13 COVID-19 and Schools, COVID-19 and Scott Atlas, and COVID-19 Policy on Apple Podcasts
Show Plenary Session, Ep 3.13 COVID-19 and Schools, COVID-19 and Scott Atlas, and COVID-19 Policy – Sep 24, 2020
Related Articles
Grilling the data: application of specification curve analysis to red meat and all-cause mortality
To present an application of specification curve analysis—a novel analytic method that involves defining and implementing all plausible and valid analytic approaches for addressing a…
Grilling the data: application of specification curve analysis to red meat and all-cause mortality
To present an application of specification curve analysis—a novel analytic method that involves defining and implementing all plausible and valid analytic approaches for addressing a…
Preventive Coronary Stents: Not There Yet
The PREVENT trial on stenting stable plaques deemed vulnerable by imaging criteria suggests a benefit over medical therapy alone. John Mandrola, MD, finds it provocative…
Grilling the data: application of specification curve analysis to red meat and all-cause mortality
To present an application of specification curve analysis—a novel analytic method that involves defining and implementing all plausible and valid analytic approaches for addressing a…
Preventive Coronary Stents: Not There Yet
The PREVENT trial on stenting stable plaques deemed vulnerable by imaging criteria suggests a benefit over medical therapy alone. John Mandrola, MD, finds it provocative…
We’re Number One—Thanks to You
You’re one of 630,591 Free Pressers. Help us make you one in a million.
Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI
REDUCE-AMI showed no benefit for routine beta-blockers post–MI in patients with normal ejection fraction. John Mandrola, MD, asks: Does evidence-based medicine need expiration dates?
Impella Saves Live in CS, but Patient Selection Key
In the first randomized trial of Impella in a select group of patients with AMI and cardiogenic shock, the device saved lives. The high rate…
Impella Saves Live in CS, but Patient Selection Key
In the first randomized trial of Impella in a select group of patients with AMI and cardiogenic shock, the device saved lives. The high rate…